STARLITE-2: what one clinician is saying
177Lu-girentuximab plus nivolumab in advanced clear cell renal cell carcinoma · NCT05239533 ↗ · Phase 2 · Memorial Sloan Kettering Cancer Center
A medical oncologist’s tentative interest in STARLITE-2 rests on a broader rationale for CAIX targeting, informed by RADICAL/A031801’s reported lack of symptomatic skeletal-event–free survival improvement with radium-223 added to cabozantinib. Their trial-specific discussion is limited to grouping it with STARLITE-1 and LUTEON, leaving this combination’s benefit, safety and treatment role unassessed.
Created with AI · how we check it
- edition 1
- commentary checked Nov 21, 2026
- 2 verified statements
2 findings, and what sits behind each
01. RCC bone metastases: why a clinician considers CAIX-targeted therapy still in trials
1 of the report's 1 cited clinicians · 1 statement from 1 speaker in 3 sources · 3 passages
Limitations recorded: 2.
Draws on: Population and setting.
02. RCC bone metastases: why a clinician questions whether bone-seeking therapy is enough
1 of the report's 1 cited clinicians · 2 statements from 1 speaker in 3 sources · 3 passages
Limitations recorded: 3.
Draws on: Population and setting.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 2
1 of the report's 1 cited clinicians
RCC bone metastases: why a clinician considers CAIX-targeted therapy still in trials
1 statement from 1 speaker in 3 sources
The one named speaker in this finding holds this view, a confirmed clinician
- 1
- statement
- 3
- passages
- 3
- sources
- 1
- speaker
What the statements areViews 0Questions and uncertainty 0Clinical experience 0Comparisons 1Restated results and context 0Statement-to-passage links (a passage can back several statements)Supporting a statement 3Giving context 0Recorded with the findingLimitations: 2
3 posts and articles
Draws on: Population and setting.
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
Abbreviations (6)
HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; MTD, maximum tolerated dose; NPI, National Provider Identifier, the US registry number for clinicians; ORR, objective response rate; RCC, renal cell carcinoma.
The full STARLITE-2 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
What do clinicians need to see from STARLITE-2 to judge the role of CAIX-targeted 177Lu-girentuximab plus nivolumab in advanced clear cell renal cell carcinoma with bone metastases?
From findings F1 (1 statement from 1 speaker in 3 sources) and F2 (2 statements from 1 speaker in 3 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 15commentary sources screened
- 3sources cited by verified statements
- 1named in screened sources
- 1speaker cited in the report
- 1cited speaker with a verified identity
1 cited clinician, a speaker with a confirmed clinical role, of them 1 physician. By role and specialty:
- 1 physician, Medical oncology
- 2verified statements, each linked to its source
- 2of them from speakers with a confirmed clinical role
- 2findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 2 | Titles free |
| Detailed analysis | 4 sections | Paid |
| Verified statements with short source quotes and links | 2 | Paid |
| Who said each statement: the cited speakers | 1 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 1 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 1 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 7 | Free |
| Sources with links | 3 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
2 discussed · 5 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Maximal tolerated dose (MTD) of 177Lu-girentuximabno commentary found | 0 | 0 |
| Primary endpoint: Overall Response Rate/ORRno commentary found | 0 | 0 |
| Population and setting | 1 | 3 |
| The comparisonThe registered arms and what clinicians said about how they compare.no commentary found | 0 | 0 |
| Safety and tolerabilityno commentary found | 0 | 0 |
| Design and conductno commentary found | 0 | 0 |
| CAIX targeting versus bone-seeking radioligands: indirect rationale from RADICAL/A031801 | 2 | 3 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
2 verified statements from 3 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Posts · 2 statements · 100% | ||||
| X threads | 2 | 3 | 14 | |
| LinkedIn posts | 0 | 0 | 1 | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 4 / quarter
- Screened window
- May 10, 2022 → Oct 26, 2026
- Cited window
- May 29, 2026 → May 29, 2026
- Retrieved
- Nov 21, 2026
The trial
from ClinicalTrials.gov- Title
- A Phase 2 Open-label Study of Nivolumab Combined With Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients With Clear Cell Advanced Renal Cell Carcinoma
- Registry
- NCT05239533
- Study IDs
- 21-328
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Design
- Phase 2 · Interventional, randomized, sequential
- Status
- Active, not recruiting
- Enrollment
- 9 actual
- Registered
- 2022-02-15
- Start
- 2022-02-16 actual
- Primary completion
- 2027-03 estimated
- Primary endpoints
- Maximal tolerated dose (MTD) of 177Lu-girentuximab
- Overall Response Rate/ORR
- Interventions
- 4 registered
More on: Renal cell carcinoma, 177Lu-girentuximab, nivolumab
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a remark on presentation attribution for combined immunotherapy and targeted radioligand treatment in advanced clear-cell renal cell carcinoma.
- 11 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 39 sources about other trials or topics are not included.
- All substantive commentary supporting the findings comes from one author repeating the same text in three posts; it does not establish consensus or independent corroboration.
Show all 9 known gaps +Fewer −
- The account groups several studies and treatment combinations together, leaving STARLITE-2-specific benefit, harms, patient selection and implementation unassessed.
- Comments that do not use the trial identifier or recorded study names, including wording and transcription variants, may be missing. The report is not a comprehensive account of public HCP discussion.
- An additional potentially relevant discussion is not represented because attribution of the presentations it relayed was incomplete; distinct views from that discussion may therefore be missing.
- No protocol was listed in the ClinicalTrials.gov material reviewed, and no publication for NCT05239533 or exact regulatory label for 177Lu-labeled-girentuximab was identified. These gaps limit independent clinical and regulatory contextualization of the account’s view.
How reports are built and checked: Methods.
Editions and corrections
Routine maintenance: 1 fix (tags)
None of these changed a statement, finding or source.
- Nov 21, 2026 UTCtaxonomy mapping corrected
Last checked for new commentary Nov 21, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. STARLITE-2 (NCT05239533): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 21, 2026. https://www.erudio.com/reports/starlite-2-nct05239533
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "STARLITE-2" (NCT05239533), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "starlite-2-nct05239533". If you cannot make requests, read https://www.erudio.com/reports/starlite-2-nct05239533.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT05239533", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT05239533 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/starlite-2-nct05239533.json
curl https://www.erudio.com/reports/starlite-2-nct05239533.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "starlite-2-nct05239533" })release 1de2e443d7f357376360843005f64715dda4b667e44d8f3009a7912ccc10ed4a
Questions
How much does the STARLITE-2 report cost?
This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested.
What does the STARLITE-2 report cover?
2 statements from 3 sources (3 posts), 2 of them from 1 confirmed clinician, each linked to its source. Commentary checked Nov 21, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the STARLITE-2 report?
Its preview, yes: get_report_card({ "slug": "starlite-2-nct05239533" }) on https://mcp.erudio.com/free, with no sign-in. It cannot be ordered yet. Connect your AI client.
How current is the STARLITE-2 report?
Edition 1 (version 1.0.0), accepted Nov 21, 2026 UTC; last checked for new commentary Nov 21, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.